Constitutionality of new drug-pricing policy stirs debate

Published: 2007-02-27 07:00:00

Updated: 2007-02-27 07:00:00

Amid an intensifying dispute over the ongoing new drug-pricing policy, a fresh debate over the constitutionality of so-called positive list system has arisen.

98 pharmaceutical firms of the Korea Pharmaceutical Manufacturers Association (KPMA) are seeking legal means to stop the law from going...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK